A Study of IMC-1 In Patients With Fibromyalgia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01850420
Recruitment Status : Completed
First Posted : May 9, 2013
Last Update Posted : March 27, 2015
Information provided by (Responsible Party):
Innovative Med Concepts, LLC

May 7, 2013
May 9, 2013
March 27, 2015
May 2013
January 2014   (Final data collection date for primary outcome measure)
Change in pain from baseline [ Time Frame: 16 weeks ]
Comparison of the change from baseline in patient self reported pain scores between IMC-1 and placebo treatment, over 16 weeks of treatment
Same as current
Complete list of historical versions of study NCT01850420 on Archive Site
  • Patient Global Impression of Change [ Time Frame: 16 weeks ]
    Patients will rate their global improvement over the duration of the trial
  • Fibromyalgia Impact Questionnaire [ Time Frame: 16 weeks ]
Same as current
Not Provided
Not Provided
A Study of IMC-1 In Patients With Fibromyalgia
A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia
This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Fibromyalgia
  • Chronic Pain
  • Myofascial Pain
Drug: IMC-1
  • Experimental: IMC-1
    Experimental intervention
    Intervention: Drug: IMC-1
  • Placebo Comparator: Matching placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2014
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of fibromyalgia
  • English speaker

Exclusion Criteria:

  • Rheumatologic diseases
  • Bipolar disease, OCD, severe anxiety, schizophrenia
  • Systemic infection, severe cardiac disease, chronic steroid usage
  • chronic opioid usage
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Innovative Med Concepts, LLC
Innovative Med Concepts, LLC
Not Provided
Not Provided
Innovative Med Concepts, LLC
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP